It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine.
It is clinically significant only in patients enrolled in clinical trials to assess loviride (e.g., CAESAR and AVANTI), as loviride was frequently administered alone without a companion drug, increasing the likelihood of developing reverse transcriptase mutations like K103N that confer cross-class resistance to NNRTIs such as efavirenz and nevirapine.